Glucagon Receptor Agonist¶

Quick Facts¶

Development Code	LY3437943
Peptide Class	Multi-Receptor Agonist (Triple Agonist)
Molecular Targets	GLP-1 Receptor (GLP-1R), GIP Receptor (GIPR), Glucagon Receptor (GCGR)
Amino Acid Length	Modified peptide (derived from native incretin/glucagon sequences)
Half-Life	Approximately 6–7 days (once-weekly dosing)
Developer	Eli Lilly and Company
Current Development Phase	Phase 3 clinical trials
Primary Research Indications	Type 2 diabetes, obesity, non-alcoholic steatohepatitis (NASH)
Key Structural Feature	Engineered peptide with balanced receptor activity across GLP-1R, GIPR, and GCGR

Executive Summary¶

Retatrutide (LY3437943) is an investigational synthetic peptide engineered as a triple agonist at the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR).

Developed by Eli Lilly and Company, retatrutide represents a further evolution of multi-receptor metabolic peptide pharmacology beyond the dual agonism of tirzepatide.

By simultaneously activating three metabolically relevant receptor pathways, retatrutide aims to achieve enhanced glycemic control, superior body weight reduction, and beneficial effects on hepatic steatosis through complementary and synergistic mechanisms.

Phase 2 clinical data published in The New England Journal of Medicine and The Lancet have demonstrated substantial efficacy in both type 2 diabetes and obesity, with some participants achieving body weight reductions exceeding 24%.

Background¶

The development of retatrutide emerged from the recognition that the coordinated actions of multiple nutrient-regulated hormones—GLP-1, GIP, and glucagon—produce more robust metabolic effects than any single pathway alone.

Native GLP-1 and GIP are incretin hormones secreted from intestinal cells that stimulate glucose-dependent insulin secretion, while glucagon (secreted from pancreatic alpha cells) primarily acts to raise blood glucose through hepatic gluconeogenesis and glycogenolysis.

However, when combined in a balanced pharmacological context, glucagon receptor activation can complement GLP-1 and GIP activity by increasing energy expenditure and hepatic lipid oxidation. Rational multi-receptor agonist design requires precise balancing of relative receptor potencies to maximize therapeutic benefit while minimizing adverse effects.

Coskun and colleagues reported the preclinical pharmacology of LY3437943, demonstrating that an optimized ratio of GIPR/GLP-1R/GCGR activation produces superior weight loss and glycemic improvement compared to dual agonists in preclinical models.

The GIP receptor agonism component was noted to potentially mitigate gastrointestinal tolerability issues associated with strong GLP-1R activation, while the glucagon receptor agonism component contributes to increased energy expenditure and hepatic fat reduction.

Scientific Explanation¶

Retatrutide is a synthetic 39-amino acid peptide engineered through systematic structure-activity relationship optimization of native peptide hormone sequences. The peptide incorporates fatty acid acylation to enable albumin binding and extend its circulating half-life to approximately 6–7 days, permitting once-weekly subcutaneous administration. The molecular structure is designed to activate all three class B G protein-coupled receptors—GLP-1R, GIPR, and GCGR—with balanced potencies that reflect the physiological interplay of these hormone systems. At the molecular level, retatrutide binds to the extracellular domains of each receptor, inducing conformational changes that activate intracellular Gαs-mediated signaling cascades. Detailed signaling studies indicate that retatrutide engages G protein-dependent pathways (cAMP production) at each receptor, while the profile of β-arrestin recruitment varies across the three receptors. This biased signaling profile may contribute to the differentiated efficacy and tolerability profile observed in clinical studies.

Mechanism¶

Retatrutide exerts its metabolic effects through the coordinated activation of three distinct receptor pathways: GLP-1 Receptor Activation: GLP-1R signaling potentiates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, delays gastric emptying, and promotes satiety through central nervous system actions. These effects are well-established from extensive GLP-1 receptor agonist research. GIP Receptor Activation: GIPR signaling complements GLP-1 effects through direct insulinotropic action on beta cells (particularly in the euglycemic state) and through effects on adipose tissue lipid metabolism. GIP receptor activation may also play a role in improving beta cell survival and function, and has been proposed to counteract some of the gastrointestinal adverse effects associated with GLP-1R activation. Glucagon Receptor Activation: GCGR stimulation promotes hepatic glucose production acutely, but in the context of concurrent GLP-1R and GIPR activation, the net effect is favorable for weight loss and hepatic steatosis reduction. Chronic GCGR activation increases energy expenditure, enhances fatty acid oxidation in the liver, reduces hepatic triglyceride content, and promotes hepatic mitochondrial function. The combination of GLP-1R-mediated appetite suppression with GCGR-mediated increases in energy expenditure produces additive or synergistic effects on body weight.

Research Evidence¶

Preclinical pharmacology studies by Coskun et al. characterized retatrutide's in vitro potency and in vivo efficacy. In diet-induced obese mouse models, retatrutide produced dose-dependent body weight reductions exceeding those of selective GLP-1R agonists and GLP-1R/GIPR dual agonists, with concurrent improvements in glycemic control and hepatic steatosis. The triple agonist approach demonstrated a favorable therapeutic index with acceptable gastrointestinal tolerability in animal models. Phase 1 clinical trials established the safety and pharmacokinetic profile of retatrutide in healthy volunteers and participants with type 2 diabetes.

The phase 2 trial for type 2 diabetes enrolled 281 participants across multiple dose cohorts and demonstrated significant reductions in HbA1c (up to −2.02% from baseline) and body weight (up to −16.5% from baseline) over 48 weeks.

The phase 2 obesity trial, published in The New England Journal of Medicine by Jastreboff and colleagues, enrolled 338 adults with obesity and reported mean body weight reductions of up to 24.2% at 48 weeks with the highest dose (12 mg), the largest weight reduction reported for any pharmacotherapeutic intervention to date.

Notably, the weight reduction trajectory had not plateaued at 48 weeks in the highest-dose group, suggesting the potential for even greater efficacy with longer treatment duration.

The most common adverse events were gastrointestinal (nausea, diarrhea, vomiting), consistent with the GLP-1R agonist class, and were predominantly mild to moderate in severity and diminished over time.

Current Understanding¶

The scientific community recognizes retatrutide as a pioneering triple-receptor agonist that validates the multi-hormone pharmacological approach for metabolic disease.

The clinical evidence demonstrates that coordinated activation of GLP-1R, GIPR, and GCGR can achieve weight reductions approaching the range typically associated with bariatric surgery, suggesting a major advance in obesity pharmacotherapy.

The triple agonism approach appears to engage complementary mechanisms of action—appetite suppression via GLP-1R, enhanced incretin effects via GIPR, and increased energy expenditure via GCGR—to produce the observed metabolic benefits.

Ongoing phase 3 clinical trials are evaluating retatrutide in larger populations for type 2 diabetes, obesity, and NASH. The NASH program is of particular interest given the potential for glucagon receptor-mediated hepatic lipid oxidation to reduce liver fat content and improve histological outcomes in non-alcoholic steatohepatitis.

Important research questions remain, including the long-term cardiovascular safety and efficacy profile, optimal dosing strategies, durability of weight loss, and potential for rebound metabolic effects upon treatment discontinuation.

Future Research¶

Several critical research directions for retatrutide warrant attention. First, the phase 3 cardiovascular outcomes trial will assess the impact of triple-receptor agonism on major adverse cardiovascular events (MACE), building on the cardioprotective effects established for GLP-1 receptor agonists.

Second, the NASH program will evaluate whether the glucagon receptor component translates into improved histological outcomes for non-alcoholic steatohepatitis, a condition with limited pharmacotherapeutic options.

Third, long-term extension studies will provide essential data on the durability of weight loss maintenance, metabolic adaptation, and safety beyond 2 years of treatment. Fourth, investigations into potential applications in prediabetes, metabolic syndrome, and cardiovascular risk reduction are anticipated.

Finally, comparative effectiveness research against bariatric surgery and other intensive lifestyle interventions will help establish the clinical positioning of triple-receptor agonism in the treatment spectrum of obesity.

Frequently Asked Questions¶

What distinguishes retatrutide from tirzepatide?

Retatrutide adds glucagon receptor agonism to the GIP/GLP-1 dual agonism of tirzepatide. This triple-receptor approach is designed to further increase energy expenditure and hepatic lipid oxidation beyond what dual agonism alone can achieve, potentially resulting in greater weight loss and improved liver fat reduction.

How does retatrutide achieve once-weekly dosing?

Retatrutide incorporates a fatty acid side chain that binds non-covalently to serum albumin. This albumin binding slows renal clearance and enzymatic degradation, extending the peptide's half-life to approximately 6–7 days and enabling therapeutic concentrations with once-weekly subcutaneous administration.

What weight reduction has been observed with retatrutide?

In the phase 2 obesity trial, participants receiving retatrutide 12 mg once weekly experienced mean body weight reductions of up to 24.2% at 48 weeks. Notably, weight loss had not plateaued at the end of the treatment period, suggesting potential for further reduction with extended treatment duration.

What are the primary adverse effects reported?

Gastrointestinal adverse effects including nausea, diarrhea, and vomiting are the most commonly reported events, consistent with the GLP-1 receptor agonist class. These effects are primarily mild to moderate in severity and tend to diminish with continued dosing as tolerance develops.

Is retatrutide being studied for non-alcoholic steatohepatitis (NASH)?

Yes. The glucagon receptor agonism component is hypothesized to reduce hepatic steatosis through increased fatty acid oxidation and mitochondrial function in hepatocytes. Phase 2 and phase 3 clinical programs are evaluating retatrutide for the treatment of NASH with fibrosis.

How does glucagon receptor agonism contribute to weight loss?

Glucagon receptor activation increases energy expenditure through enhanced thermogenesis and fatty acid oxidation. While glucagon alone would raise blood glucose, concurrent GLP-1R activation mitigates this hyperglycemic effect, allowing the energy expenditure benefits of GCGR stimulation to be realized without net glucose elevation.

What is the dosing schedule used in clinical trials?

Clinical trials have employed a dose-escalation regimen over several weeks to improve gastrointestinal tolerability, starting at low doses (2 mg) and titrating up to target doses (4 mg, 8 mg, or 12 mg) administered once weekly via subcutaneous injection.

Does retatrutide have effects on cardiovascular risk factors?

Phase 2 data have demonstrated improvements in blood pressure, lipid profiles (reduced triglycerides, LDL cholesterol), and inflammatory markers in addition to glycemic and weight effects. A dedicated cardiovascular outcomes trial (phase 3) is ongoing to evaluate MACE reduction.

What are the limitations of current retatrutide research?

Current limitations include the relatively short duration of clinical studies (≤48 weeks), the need for larger and more diverse participant populations, and the absence of long-term cardiovascular outcomes data. Additionally, the durability of weight loss after treatment cessation and the effects of retatrutide on lean body mass require further investigation.

How does retatrutide compare to bariatric surgery in terms of efficacy?

The 24.2% mean weight reduction observed with retatrutide approaches the range typically reported after bariatric surgical procedures such as sleeve gastrectomy (25–30%), representing a substantial advancement in non-surgical obesity pharmacotherapy. Direct comparative trials between retatrutide and bariatric surgery have not yet been conducted.

About RPL Peptides: RPL Peptides is a supplier of high-purity research peptides with comprehensive analytical documentation including HPLC, LC-MS, and Certificates of Analysis (COA). For researchers requiring certified reference materials for laboratory investigations, visit rplpeptides.com or explore detailed molecular data at the RPL Peptides Data Center.

References¶

The Lancet

New England Journal of Medicine

The Lancet

Diabetes, Obesity and Metabolism

Nature Medicine

Frontiers in Physiology

Endocrine Reviews

Trends in Endocrinology & Metabolism

Diabetes

Molecular Metabolism

— Written by the RPL Scientific Editorial Team | Last updated July 2025